Date: 2015-04-29
Type of information: Results
phase: 1
Announcement: results
Company: Arena Pharmaceuticals (USA - CA)
Product: APD371
Action
mechanism: cannabinoid receptor agonist. APD371 is an orally available agonist of the CB2 receptor is Arena\'s internally discovered investigational drug candidate for several potential indications, including pain and fibrotic diseases. This compound, through its high level of observed selectivity for the CB2 receptor versus the CB1 receptor, is designed to provide pain relief without psychotropic effects or the potential for dependence or abuse. Preclinical efficacy with APD371 has been shown in animal models of osteoarthritic and neuropathic pain.
Disease: pain, fibrotic diseases
Therapeutic area: CNS diseases - Fibrotic diseases
Country:
Trial details:
Latest
news: * On April 29, 2015, Arena Pharmaceuticals announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor currently in development for the treatment of pain and potentially fibrotic diseases. The randomized, double-blind and placebo-controlled Phase 1 clinical trial enrolled 56 healthy adults to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD371. Dose responsive exposure was observed over the explored dose range of 10-400 mg with good tolerability at all doses administered.
